The things that we set about doing at the beginning, and the different strategies that came out of it, are all moving forward. The thing that’s pleasing to me is that the slow build seems to be sustained. I had not been in academia or in the early-stage space for quite a while, and spent some time with the first two or three people that we hired, and it’s been building slowly since then. What’s most exciting is that we set out to rebuild the program post-Covid after it cratered for a variety of reasons at Duke.
I think the university providing this resource, and being thoughtful about the fact that you have to stand up the companies carefully at the beginning, is great because we haven’t had that sort of resource at Duke before. It provides resources, which are mainly experienced people, to give a level of advocacy to the startup company. What exciting thing has happened recently for you or your organization?Īt a really high level, the purpose of Duke New Ventures is to have more startups coming out of Duke and to have those startups have a higher probability of success than has been the case in the past. I just like to have my phone and keys and not too much else. Jeff received his PhD in Neurobiology from Duke University School of Medicine and his BS degree in Economics and Biology from Duke University. He is passionate about new technology development and maximizing the odds new products will achieve their potential to improve human life through business success.
Jeff’s previous experiences include Smith and Nephew, Nanosyn, and Square 1 Bank, where he has participated in the development, financing, licensing, acquisition, and commercialization of innovative new technologies in multiple life science and healthcare fields. Jeff Welch joined the Duke Office for Translation and Commercialization (“OTC”) as Director of New Ventures in early 2021 after five years as Bioventus’ executive responsible for all corporate development activities.
0 kommentar(er)
